Comprehensive geriatric assessment modifies treatment plans and associates with survival in older adults with gastrointestinal malignancies
Does a pre-surgery check-up actually change treatment plans and help older adults with cancer live longer?
This retrospective cohort study evaluated 273 adults aged ≥65 years referred for preoperative comprehensive geriatric assessment (CGA) at a …
A pre-surgery health check changed treatment plans for 21% of older cancer patients and was linked to better survival.
CT radiomics and transcriptomics predict chemotherapy response in advanced laryngeal cancer
New Scan Predicts Chemo Success Before Treatment Starts
A retrospective cohort study of 161 advanced laryngeal cancer patients found that a Random Forest model combining CT radiomics, transcriptom…
A new scan using CT images can predict if chemotherapy will work for advanced laryngeal cancer before treatment begins, helping doctors avoi…
CLEC14A methylation marker detects HSIL and cervical cancer with 100% sensitivity and 95.3% specificity in a cohort of 431 participants
Can a simple blood test spot dangerous cervical cell changes before they become cancer?
This cohort study of 431 participants evaluated the CLEC14A cg05057720 methylation marker for detecting high-grade squamous intraepithelial …
A new blood test marker detects every case of dangerous cervical cell changes while correctly identifying normal tissue in over 95% of cases…
Classification framework shows 79% to 98% performance for oral squamous cell carcinoma on histopathological images
AI Learns to Ignore Stains to Spot Mouth Cancer
A computer-aided classification study evaluated a framework combining staining-bias suppression and structured multiple-instance aggregation…
New AI technology learns to ignore stain colors, helping doctors spot mouth cancer more accurately even when lab dyes vary.
Plasma metabolomics panels show high discriminating power for lung, colorectal, and ovarian cancers
Blood Test Finds Unique Chemical Fingerprints for Three Major Cancers
This metabolomics biomarker discovery study analyzed plasma from 615 patients with lung, colorectal, or ovarian cancer and 95 non-cancerous …
A new blood test finds unique chemical fingerprints for lung, ovarian, and colorectal cancers with high accuracy before tumors are visible.
Camonsertib plus gemcitabine shows preliminary activity in advanced solid tumors with DDR alterations
New Drug Combo Helps Some Solid Tumors Grow Slower
This Phase Ib trial evaluated camonsertib plus gemcitabine in 76 patients with advanced solid tumors harboring DDR gene alterations.
This combination might offer a new hope for patients whose tumors have stopped responding to standard treatments.
Pirtobrutinib shows activity in relapsed and refractory marginal zone lymphoma patients in a Phase 1/2 trial
Early trial shows pirtobrutinib helped some patients with relapsed marginal zone lymphoma
This Phase 1/2 trial evaluated pirtobrutinib in 36 patients with relapsed and refractory marginal zone lymphoma.
A new drug helped more than half of patients with relapsed lymphoma shrink their tumors, offering hope for those who have run out of other t…
Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients
New Drug Combo Stops Breast Cancer Growth
This Phase 1 study enrolled 34 evaluable patients with previously treated triple-negative, hormone-resistant, or HER2-negative metastatic br…
This new combination may help some patients keep their cancer stable for months when other options have run out.
Lirafugratinib sequencing with futibatinib shows feasibility in FGFR2-driven cancers based on early-phase trial data
Can a new cancer drug work better if you switch to another drug after it stops?
This Phase I/II preprint trial evaluated lirafugratinib in 30 patients with FGFR2-driven cancers, including intrahepatic cholangiocarcinoma.
When a cancer drug stops working, switching to a different one might help because the two medicines attack the disease in slightly different…
Early study of CDP1 plus chemotherapy showed promising activity and manageable safety in advanced penile cancer
New Drug Combo Shrinks Advanced Penile Cancer Tumors
This prospective phase 1 study evaluated the safety and antitumor activity of CDP1 monotherapy or in combination with standard chemotherapy …
A new drug combo shrinks advanced penile cancer tumors, offering fresh hope for patients with rare, hard-to-treat disease.
HS-20093 shows response in lung cancers in Phase 1a/b trial
New Drug Targets Deadly Lung Cancer Cells
A Phase 1a/b trial in 306 patients with previously treated advanced solid tumors found HS-20093, a B7-H3-targeted antibody-drug conjugate, h…
A new drug attacks a specific protein on lung cancer cells, helping more than half of patients with an aggressive type while remaining safe …
Multi-cancer early detection blood test shows variable sensitivity across cancer stages in case-control study
Blood Test Finds Half of Cancers Before Symptoms Start
This case-control study evaluated a multi-target blood test for early cancer detection across 21 tumor types in 6,352 samples.
A new blood test detects half of all cancers before symptoms appear, catching aggressive types often missed by current screening tools.